World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 25 March 2013
Main ID:  NCT01286779
Date of registration: 26/01/2011
Primary sponsor: Baxter Healthcare Corporation
Public title: BAX 326 (rFIX) Continuation Study
Scientific title: BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study
Date of first enrolment: April 2011
Target sample size: 100
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
Key inclusion & exclusion criteria

Main Inclusion Criteria:

- Subject and/or legal representative has/have voluntarily provided signed informed

- Subject has completed Baxter clinical study 250901 (pivotal study) or Baxter clinical
study 251101 (pediatric study)

- Subject was 12 to 65 years old at the time of screening for Study 250901 or < 12
years old at the time of screening for Study 251101

- Subject has severe (FIX level < 1%) or moderately severe (FIX level 1-2%) hemophilia
B (based on the one stage activated partial thromboplastin time (aPTT) assay), as
tested at screening at the central laboratory

- Subject has not developed an inhibitory FIX antibody during Baxter Pivotal Study
250901 or Pediatric Study 251101

Main Exclusion Criteria:

- Subject received factor IX product(s) other than BAX 326 upon completion of Baxter
Pivotal Study 250901 or Pediatric Study 251101

- Subject has been diagnosed with an acquired hemostatic defect other than hemophilia B

- For subjects transferring from Pivotal Study 250901: Subject's weight is < 35 kg or >
120 kg

- Subject is planned to take part in any other clinical study, with the exception of
BAX 326 Surgery study as described in this protocol, during the course of the
Continuation Study

Age minimum: N/A
Age maximum: 65 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Hemophilia B
Biological: BAX 326 (Recombinant factor IX)
Primary Outcome(s)
Adverse events possibly or probably related to the investigational product [Time Frame: Assessed (based on patient diary) every 3 months until study completion]
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Baxter Innovations GmbH
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history